Menu
  • Home
  • London Exchange
  • Euronext
  • Australian Exchange
  • Wire
  • Contact Us
  • Business & Finance
NewsnReleases

Merck appoints Deborah H. Telman as General Counsel for Organon & Co

Posted on July 9, 2020

Merck appoints Deborah H. Telman as General Counsel for Organon & Co 1KENILWORTH: Merck, known as MSD outside the United States and Canada, announced the appointment of Deborah H. Telman as General Counsel for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses.

In her new role, Deb will act as senior legal advisor to the Board of Directors, Chief Executive Officer and senior management and will be responsible for the company’s worldwide legal affairs, compliance and global environmental health & safety.

She will join Organon from Sorrento Therapeutics where she served as Senior Vice President, General Counsel and Corporate Secretary leading the legal, compliance, human resource and quality functions. Deb has spent more than 20 years in senior executive roles at several global companies including Abbott, Johnson Controls and Boeing. She also brings deep experience in mergers and acquisitions, including a major pharmaceutical spinoff with Abbott at the time of its spin from AbbVie.

“Deb’s proven leadership, industry knowledge and expertise will serve Organon employees, customers and shareholders well,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “Her counsel will help set the new company on a path to positively impact the lives of patients and improve public health.”

“I am very pleased and excited to have Deb join us and direct our legal, compliance and health and safety strategies at Organon,” said Kevin Ali, appointed chief executive officer of Organon. “Her experience and expertise will be fundamental in advancing Organon & Co.’s vision to be the world’s leading women’s health company.”

The appointment of the General Counsel marks another important milestone as Merck prepares Organon & Co. to operate independently. The spinoff transaction is on track for completion in the first half of 2021. For further information, please visit https://merck.unleashinggrowthpotential.com

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Track all markets on TradingView

Investing.comThe Exchange Rates are powered by Investing.com.

Site Navigation

  • Home
  • Listed Companies
  • Contact Us
  • London Stock Exchange
  • Singapore Exchange
  • Canadian Exchange
  • Australian Exchange
  • Oslo Bourse
  • PSX
  • Ratings
  • Euronext
  • MENA
  • Nasdaq Nordic
  • Wire
  • Business & Finance
  • Gadget Reviews
  • About Us: A Comprehensive Financial News Database

All news and articles on NewsnReleases are based on press releases, corporate announcements and analysts’ reports issued to London Stock Exchange (LSE), Euronext, Singapore Exchange (SGX), Japan Stock Exchange (JPX), Dubai Financial Market (DFM), Saudi Stock Exchange (Tadawul), Qatar Stock Exchange (QSE), BSEIndia, Australia Stock Exchange etc.

Listed Companies

Equity Markets and Stock Exchanges

NNR
©2025 NewsnReleases | WordPress Theme by Superb WordPress Themes